6 results
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
RIPE Therapy - Drug ... Microbiologically Confirmed Pulmonary ... Tuberculosis - ... #medications #pharmacology ... #Treatment
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... Candidiasis in HIV-AIDS ... antifungals are required ... candida #mucosal #IDSA ... infections #HIVAIDS #pharmacology
CNS Infection in HIV / AIDS - Differential Diagnosis Framework

Principles of HIV-Associated CNS Opportunistic Infections:
 •
Antimicrobial treatment ... is generally required ... 80% sensitive Tuberculous ... - Hemorrhage, tuberculomas ... opportunistic #InfectiousDiseases
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
IDSA Recommendations ... Coccidiodomycosis in HIV-AIDS ... Infection (Diffuse Pulmonary ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
Nontuberculous Mycobacteria (NTM) Infections 

Mycobacterial species other than those belonging to the Mycobacterium tuberculosis complex and
Mycobacterium tuberculosis ... mucogenicum • HIV ... Complex (MAC): • Acquired ... Advanced HIV (CD4 ... differential #diagnosis #infectiousdiseases
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Mycobacterium Tuberculosis ... result Preferred Therapy ... (Duration of Therapy ... infections #HIVAIDS #pharmacology